Clinical Study
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Table 3
Change of parameters after administration of sitagliptin.
| | Sitagliptin (N = 36) | | | Variables (N) | Before administration | After administration | Paired t-test | | P value |
| | Body weight* (kg) | 81.1 (68.4–88.9) | 80.7 (68.7–86.3) | 0.39 | | BMI* (kg/m2) | 29.4 (25.0–31.3) | 29.2 (25.5–31.2) | 0.56 | | AST* (IU/mL) | 47 (36–56) | 44 (30–45) | 0.47 | | ALT* (IU/mL) | 75 (55–89) | 61 (40–74) | 0.03 | | γ-GTP* (IU/mL) | 89 (47–116) | 75 (43–100) | 0.01 | | Fast blood glucose* (mg/dL) | 175 (138–201) | 152 (128–187) | <0.01 | | HbA1c (%) | 8.4 (7.5–9.5) | 7.3 (6.5–7.8) | <0.01 | | LDL-cholesterol* (mg/dL) | 126 (104–148) | 113 (97–129) | 0.02 | | Triglyceride* (mg/dL) | 175 (114–229) | 166 (99–195) | 0.60 | | Platelet count* (/L) | 216 (166–248) | 202 (162–240) | <0.01 | | APRI index* | 0.64 (0.44–0.76) | 0.60 (0.39–0.63) | 0.47 |
|
|
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; γ-GTP: γ-glutamyl transpeptidase; HbA1c: hemoglobin A1c; APRI: AST-to-platelet counts ratio index.
|
